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The sub-acute toxicity of E. faecalis HZNU P2 was investigated in rats fed with different doses for 14 days. To 
evaluate the acute oral toxicity of E. faecalis HZNU P2, rats were fed with E. faecalis HZNU P2 at a high dose of 
2×1011 CFU kg–1 for 10 days. Results showed that there were no abnormal clinical signs in any of the groups during 
the experiment. There were no signifi cant differences in live weight gain among rats fed with E. faecalis HZNU P2, 
compared to those in control group. Macroscopic or microscopic examinations of organs revealed no abnormalities, 
indicating that E. faecalis HZNU P2 did not adversely affect the health of rats. Results of this study demonstrated 
that digestion of E. faecalis HZNU P2 in rats did not show any obvious signs of toxicity.
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Probiotics are live microorganisms that can confer health benefit on the host when administered 
in adequate amounts (YAKABE et al., 2009, 2011; SHI et al., 2013). Many studies have shown 
that probiotics can prevent diarrhoea and many other diseases (HAMILTON-MILLER, 2004; BAI 
& OUYANG, 2006; MACH, 2006; OUWEHAND, 2007; MCFARLAND & DUBLIN, 2008; YAKABE et 
al., 2009, 2011), balance intestinal microfl ora, and stimulate the immune system (SHAH, 
2007). Recently, probiotics have received increasing attention, and many health-promoting 
probiotic-based products have been developed. As a result, more and more new specifi c 
strains of probiotic bacteria are being screened and identifi ed.
Lactic acid bacteria (LAB) have been ingested safely for many centuries and now have 
been widely used in food relevant fi elds (ZHOU et al., 2000; YAKABE et al., 2009, 2011). Many 
LAB strains, such as Lactobacillus, Bifidobacterium, Streptococcus, and Enterococcus spp., 
have abilities to inhibit the growth of many intestinal pathogens in human and animals (TSAI 
et al., 2004). This anti-microbiological action is related to many factors, including the 
production of H2O2, organic acids, and bacteriocins (NAKAI & SIEBERT, 2003; LIN et al., 2007; 
KIRTZALIDOU et al., 2011). Of LAB strains used as probiotics, there is some debate about the 
genus Enterococcus (TSAI et al., 2004). It has been isolated from many sources such as milk 
and cheese samples, human vaginal secretions, the preen gland secretion of birds, and animal 
faeces (MEDINA et al., 2001; LINAJE et al., 2004; TSAI et al., 2004; LAUKOVA et al., 2008; 
MARTIN et al., 2008; SOLER et al., 2008). It can prevent various gastrointestinal infections and 
acute enteritis (TSAI et al., 2004). However, a potential risk associated with Enterococcus 
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strains has been reported (SAFDAR et al., 2002; GOMES et al., 2008). Thus, before any 
Enterococcus strains can be incorporated into products for human or animal consumption, 
the safety of it should be carefully assessed and tested.
Recently, a new strain, E. faecalis HZNU P2, from peacock faeces has been isolated by 
our group, which has good tolerance to NaCl, low pH, and to simulated gastro-intestinal tract. 
In addition, E. faecalis HZNU P2 adhere to Hep-2 cells well, and exhibit antimicrobial 
activity against selected pathogens (results not published). It has a good potential for use as 
a probiotic in food or feed industries. In this study, to further assess the safety of this potential 
probiotic, the study of acute and sub-acute toxicity of E. faecalis HZNU P2 was performed 
in the rats. The effect of consumption of E. faecalis HZNU P2 on the health status of rats was 
studied. All the results obtained in this work will build a basis for the application of E. 
faecalis HZNU P2.
1. Materials and methods
1.1. Bacterial strains
Fresh peacock faecal samples (Hangzhou Normal University, Zhejiang, China) were 
collected, transported to the lab within 2 h, and kept refrigerated (4 °C) until the analysis. 
Faecal samples were diluted with sterile saline water (0.85%). A 100 μl diluted faecal samples 
were transferred to 10 ml bile salt broth at 37 °C for 24 h. Afterwards, serial 10-fold dilution 
of the culture was plated onto de Man, Rogosa and Sharpe (MRS, Oxoid) agar supplemented 
with 2.0% CaCO3. The plates were incubated at 37 °C for 24 h. The formed colonies on the 
plates were randomly picked and streaked on fresh MRS agar plates by dilution streaking to 
obtain single colonies. Pure culture was stored at –80 °C in MRS broth supplemented with 
50% glycerol. The strain E. faecalis HZNU P2 was identifi ed through biochemical studies, 
and 16S identifi cation according to our previous work (ZHENG et al., 2015) was used in this 
study. It was deposited in China Center for Type Culture Collection (CCTCC) under the 
preservation number CCTCC M 2014197. Stock strain was propagated in MRS broth for 24 
h and then concentrated by centrifugation. The cell pellets were re-suspended in saline 
solution at three concentrations (2×1011 CFU ml–1, 5×1010 CFU ml–1, 1×1010 CFU ml–1) after 
washing three times by sterile water. Fresh saline water was used for each sample.
1.2. Animals
Sprague–Dawley rats (25±5 g) were bred at the Animal Unit of Hangzhou Normal University. 
The rats were examined for health status on arrival and observed for 3 days before the 
experiments. After 3 days of acclimation, the rats were housed under relative humidity of 
45~50% and room temperature between 20 and 25 °C, with 12 h light-dark cycle. All 
procedures were in accordance with the Guidelines of the Animal Care and Use of Laboratory 
Animals from the Association of Laboratory Animal Science and the Center for Laboratory 
Animal Science of Hangzhou Normal University.
1.3. Acute toxic ity
For the acute toxicity assay, 40 healthy males and females were selected and randomly 
divided into 2 groups (10 rats of each sex in each group). The test strain was suspended in 
saline solution to make a concentration of 2×1011 CFU kg–1. An oral dose of 2×1011 CFU kg–1 
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test strain was administrated to the treatment group and saline solution was administrated to 
the control group twice by oral gavage (0/12 h) within 24 h. Following administration, 
clinical signs of the rats were observed for 10 days. At the end of the test, all rats were fasted 
for 12 h before anesthetization. The necropsy for the rats was performed.
1.4. Sub-acute toxicity
For the sub-acute toxicity assay, 40 healthy males and females were selected and randomly 
divided into 4 groups (5 rats of each sex in each group). The test strain was suspended in 
saline solution to make at a concentration of 2×1011 CFU kg–1 (as high dose ), 5×1010 CFU kg–1 
(as medium dose), and 1×1010 CFU kg–1 (as low dose). The test strain and saline solution was 
administrated to the treatment group and the control group by oral gavage, once per day for 
14 days, respectively. Following administration, clinical signs of the rats were observed 
every day. At the end of the test, all the rats were fasted for 12 h before anaesthetization. The 
necropsy for the rats was performed.
1.5. Clinical observations
Health status, such as abnormalities, activity, hair lustre, and mortality were observed every 
day.
1.6. Body weight
The body weight of each rat was measured every day.
1.7. Haematological and plasma biochemical examination
The animals were fasted overnight before blood collection. Blood samples were drawn into 
separate tubes containing ethylenediaminetetraacetic acid (EDTA). A PC-603 Haematology 
Analyser was used to determine haemoglobin concentration (HB), red blood cells (RBC), 
white blood cells (WBC), lymphocytes (Ly), neutrophils (Ne), and monocytes (Mo). Blood 
samples were centrifuged to obtain plasma. The biochemical parameters of plasma, including 
total protein (TP), glucose (GLU), cholesterol (CHO), and triglyceride (TG), were analysed 
by a biochemical analyser (TBA-FR40, Toshiba Co. Ltd, Osaka, Japan).
1.8. Necropsy
Following the sacrifi ce, a thorough necropsy was performed on all rats. The organs (renal, 
liver, spleen) were weighed. The organ to body weight ratios (relative organ weights) were 
calculated from the absolute organ weights and the terminal body weight of the rats. Samples 
of the weighted organs were washed by saline water and preserved in 10% formaldehyde 
solution. Histopathologic analysis was conducted on paraffi n-embedded tissues stained with 
haematoxylin and eosin. The preserved organs were observed by microscopy.
1.9. Statistics
Statistical analysis was performed using Origin 8.0 for Windows. The results are presented in 
mean value ± standard deviation (SD). The signifi cance of difference was evaluated using 
one-way analysis of variance. Duncan’s test was used to compare the signifi cance of 
differences in this paper. The differences were considered signifi cant at the level of P<0.05.
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2. Results and discussion
As stated before, many strains of probiotic bacteria have been commercialized in food or feed 
industries. Howeve r, the safety of any newly isolated strains should be studied before their 
incorporation into the products. The focus of this paper is to evaluate the safety of the strain 
E. faecalis HZNU P2 isolated from peacock faeces. A 10-days acute toxicity and a 14-days 
sub-acute toxicity of E. faecalis HZNU P2 were evaluated in rats.
2.1. Acute toxicity
Acute oral toxicity, used as a fundamental test for the safety evaluation, has been reported 
previously by many researchers (HUANG et al., 2003; TSAI et al., 2004; ENDRES et al., 2009; 
GAO et al., 2013). Regarding this, health status of animals, like activity, behaviour, and fur 
lustre, etc., is the most important indicator to evaluate the acute toxicity of the strain. In this 
study, no abnormal behaviour such as change in activity or decline in hair lustre occurred in 
rats fed with the strain E. faecalis HZNU P2 at high dose. All the rats were healthy and 
survived after 10 days. Furthermore, histopathologic analysis did not show any obvious 
differences in the appearance of visceral organs between each group. No hepatomegaly, 
splenomegaly, and any microscopic lesions in renal were observed (Fig. 1). These results 
indicated that E. faecalis HZNU P2 had no acute oral toxicity effects on general health status 
of the rats when orally administrated at high dose. This was in accordance with the findings 
of HUANG and co-workers (2003) and LEE and co-workers (2010).
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Fig. 1. Organs sections from rats treated with high dose of the strain E. faecalis HZNU P2 (2×1011 CFU kg–1) 
after 10 days of treatment 
A: Treatment by the strain E. faecalis HZNU P2; B: control group treated by saline solution
Acta Alimentaria 45, 2016
481ZHANG et al.: SAFETY EVALUATION OF ENTEROCOCCUS FAECALIS HZNU P2
2.2. Sub-acute toxicity
A 14 days sub-acute toxicity of this strain was evaluated by administrating the rats with 
different doses of the strain E. faecalis HZNU P2. During the experimental periods, there was 
no noticeable change of activity, behaviour, or hair lustre of the rats in any groups. No 
incidence of diarrhoea, constipation, or other gastrointestinal diseases related to the strain 
administration was observed. At the end of the experimental period, all rats were alive and 
healthy. In addition, the change of body weights indicated that the growth of the rats in the 
treated groups was unaffected by the administration of the strain (Fig. 2). The ratio of organ-
to-body weight is an indicator of organ infl ammation. The organ relative weights (organ 
weight/body weight ratios) in rats are shown in Figure 3. There were no signifi cant differences 
in relative weights of renal, liver, and spleen among the rats between treatment and control 
groups (P>0.05). Infectivity is an important factor in evaluating the safety of probiotic 
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Fig. 2. The body weight change of rats administrated different dosages of the strain E. faecalis HZNU P2 for 
14 days, A: Female rats; B: male rats; high dose: 2×1011 CFU kg–1; medium dose: 5×1010 CFU kg–1; low dose: 
1×1010 CFU kg–1, : Low dose; : medium dose; : high dose; : control
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bacteria. Splenomegaly and hepatomegaly are indirect indicators of infection. 
Histopathological examination of renal, liver, and spleen revealed no changes in treatment 
groups when compared to control group (Fig. 4). No macroscopic pathology fi ndings were 
observed in any organs. All these results suggest that there are no infections resulting from 
14 days treatment with the strain.
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Fig. 3. Organ weight of rats administrated different dosages of the strain E. faecalis HZNU P2 after 14 days of 
treatment high dose: 2×1011 CFU kg–1; medium dose: 5×1010 CFU kg–1; low dose: 1×1010 CFU kg–1; Control 
group treated by saline solution. : Liver, : renal, : spleen
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Fig. 4. Organs sections from rats treated with high dose of the strain E. faecalis HZNU P2 (2×1011 CFU kg–1) after 
14 days of treatment
A: Treatment by the strain E. faecalis HZNU P2; B: control group treated by saline solution
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2.3. Haematological assays
Haematological assays can be used to determine the effect of the test substance on the blood 
(TSAI et al., 2004; YAKUBU et al., 2007; LEE et al., 2010). In order to investigate the effect of 
ingestion of the strain E. faecalis HZNU P2 on blood, some haematological and plasma 
biochemical parameters were assayed, the fi ndings are shown in Table 1. It was noted that the 
strain had no adverse effects on concentrations of red blood cells, haemoglobin, white blood 
cells, lymphocytes, neutrophils, and monocytes. The cholesterol, total protein, triglycerides, 
and glucose levels in rats treated with the strain were also not significantly different from 
those of control group. This suggests that treatment of rats with the strain E. faecalis HZNU 
P2 at high dose had no adverse effects on haematological and plasma biochemical parameters. 
TSAI and co-workers (2004) also found that administration of E. faecium TM 39 to rats had 
no effects on haematology and histopathology.
Table 1. Hematologic and plasma biochemical fi ndings in rats treated with the strain E. faecalis HZNU P2 after 14 
days of treatment
Parameter High dose Medium dose Low dose Control
Male
RBC (×1012 l–1) 10.94±0.03 11.13±0.07 11.14±0.06 10.95±0.08
HB (g l–1) 133.60±2.3 137.60±3.3 135.80±2.7 132.30±1.9
WBC (×1012 l–1)
Ly (%)
Ne (%)
Mo (%)
TP (g l–1)
CHO (mmol l–1)
GLU (mmol l–1)
TG (mmol l–1)
6.05±.071
83.17±2.1
7.31±.083
6.87±0.52
160.1±3.4
8.67±0.23
10.5±0.71
4.22±0.13
5.98±0.60
83.58±1.9
7.12±0.68
6.78±0.49
159.4±3.2
8.85±0.34
10.3±0.56
4.18±0.14
6.02±0.58
83.62±1.8
6.89±0.67
6.31±0.48
161.6±3.5
8.93±0.37
10.8±0.68
4.51±0.18
6.08±0.45
84.02±2.2
6.86±0.74
6.60±0.42
163.3±3.6
9.04±0.42
10.1±0.43
4.35±0.19
Female 
RBC (×1012 l–1) 10.86±0.04 10.92±0.06 11.51±0.08 10.55±0.12
HB (g l–1) 137.40±1.9 135.80±2.1 137.60±1.5 133.80±2.5
WBC (×1012 l–1)
Ly (%)
Ne (%)
Mo (%)
TP (g l-1)
CHO (mmol l–1)
GLU (mmol l–1)
TG (mmol l–1)
6.10±0.56
79.81±2.3
6.95±0.83
6.63±0.63
160.7±3.2
8.74±0.37
9.8±0.72
4.13±0.09
6.23±0.59
83.73±3.2
7.23±0.87
6.79±0.65
161.4±3.6
8.63±0.34
10.2±0.68
4.20±0.17
6.67±0.62
84.72±3.6
7.31±0.58
6.45±0.73
163.5±3.8
8.85±0.29
10.3±0.67
4.53±0.12
5.88±0.65
83.81±2.9
7.00±0.62
6.77±0.74
162.3±2.9
8.98±0.27
10.1±0.73
4.35±0.15
3. Conclusions
Safety assessment of E. faecalis HZNU P2 isolated from peacock faeces was studied in this 
paper. The results of this study demonstrated that ingestion of E. faecalis HZNU P2 with 
different dose had no adverse effect on health, growth, haematological and histology 
parameters in rats. In addition, acute toxicity in rats fed with the strain at high dose was not 
observed. These results suggest that E. faecalis HZNU P2 is likely to be safe for animal 
consumption. All the obtained results will build a basis to develop functional products using 
the strain E. faecalis HZNU P2.
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